Roth Capital Reiterates a Buy Rating on Glaukos

By Jason Carr

In a report issued on November 11, Chris Lewis from Roth Capital reiterated a Buy rating on Glaukos (NYSE: GKOS), with a price target of $41. The company’s shares closed last Friday at $34.01.

According to, Lewis is a 4-star analyst with an average return of 4.3% and a 55.6% success rate. Lewis covers the Healthcare sector, focusing on stocks such as Cogentix Medical Inc, Trinity Biotech Plc, and Natus Medical Inc.

Currently, the analyst consensus on Glaukos is Strong Buy and the average price target is $42.50, representing a 25.0% upside.

In a report issued on October 27, Wells Fargo also initiated coverage with a Buy rating on the stock.

The company has a one year high of $39.82 and a one year low of $14.25. Currently, Glaukos has an average volume of 527.4K.

Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is negative on the stock.

Glaukos Corp. operates as an ophthalmic medical device company. Its micro invasive glaucoma surgery procedures are designed to reduce intraocular eye pressure by improving aqueous outflow through the natural physiologic pathway. The firm’s iStent technology reduces introcular pressure (IOP) by improving aqueous humor outflow. The company was founded by Olav B. Bergheim, Morteza Gharib and Richard Hill in July 1998 and is headquartered in Laguna Hills, CA.